🇺🇸

US SEC Filing Intelligence

· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 17, 2026

The September 17, 2026 filing batch reveals a pronounced shift toward passive investment (13G) filings, with 20 of 32 filings indicating no intent to influence control. Notable activist or strategic activity includes a going-private proposal for 111, Inc., a tender offer by Beretta for Sturm Ruger, and significant stake building in XBP Global Holdings by two entities. Insider activity shows a mix of confidence (Greenidge director purchase, FibroBiologics CSO investment) and exits (Cheer Holding CEO sale, Uber's Aurora block sale). Capital allocation trends include a major secondary sale by Diamondback's largest shareholder and a strategic acquisition by Hafnia in TORM. Sector themes highlight energy sector consolidation, healthcare passive accumulation, and a notable shift in voting control structures. Key catalysts include the Sturm Ruger tender offer expiry (Oct 15) and XBP registration statement deadline (Sep 22).

18 high priority 14 medium 32 total filings
· daily

S&P 500 Financials Sector SEC Filings — September 17, 2026

This digest covers 19 pre-analyzed SEC filings from the S&P 500 Financials sector, with 15 newly published since the last brief. The filings reveal a sector characterized by significant insider accumulation (notably at CME Group), a major capital return event at Morgan Stanley, and a high-yield ABS deal from Capital One. Key themes include a divergence in insider sentiment (accumulation at CME vs. selling at Robinhood and Japan Post), a shift toward passive index investing (BlackRock), and a continued focus on capital returns and balance sheet management. While no broad-based margin or revenue trends are available from the filings, the data points to selective opportunities in asset managers and exchanges, balanced by risks in fintech and consumer lending. The most material development is the Morgan Stanley tender offer, which signals a potential undervaluation of its private markets fund. Watch for the delisting of Citigroup's matured notes and continued insider activity at CME.

18 high priority 1 medium 19 total filings
· daily

S&P 500 Energy Sector SEC Filings — September 17, 2026

The 9 filings from the S&P 500 Energy sector reveal a sector in a state of operational discipline and strategic capital management, but with diverging insider sentiment. The dominant theme is the routine, non-discretionary insider activity at EOG Resources, where four top executives (including the CEO) had shares withheld for taxes, a neutral signal that does not indicate a change in management conviction. In contrast, a significant bearish signal emanates from Phillips 66, where an Executive Vice President executed a large, profitable sale ($6.2M) after exercising options, suggesting a potential top-side view. This is juxtaposed against a small, symbolic insider purchase at Texas Pacific Land Corp, which reinforces a long-term bullish narrative for that entity. The sector's capital discipline is highlighted by Expand Energy Corp's $500 million debt offering to refinance or fund operations at a fixed 5.650% rate, a move that strengthens its balance sheet but adds leverage. The lack of period-over-period financial data or forward-looking guidance in these specific filings limits trend analysis, but the insider activity patterns and capital allocation decisions provide clear, actionable signals for investors focusing on management sentiment and financial strategy within the energy complex.

9 high priority 9 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — September 17, 2026

The 9 filings in the S&P 500 Consumer Staples sector for September 17, 2026, reveal a period of steady, low-key corporate governance activity rather than operational or financial upheaval. The most significant development is PepsiCo's appointment of Johnson & Johnson Chairman and CEO Joaquin Duato to its board, a move that brings deep healthcare and multinational leadership experience and is viewed positively. The remaining filings are dominated by routine insider equity awards at Hershey and Procter & Gamble, which, while not generating strong directional signals, collectively indicate standard long-term incentive alignment. There are no period-over-period comparisons, forward-looking statements, or capital allocation changes in this batch, limiting the ability to identify broad sector trends. The lack of any bearish signals or risk flags suggests a stable, if uneventful, environment for these consumer staples giants. The primary actionable insight is the positive board refreshment at PepsiCo, while the P&G option grants to top executives signal continued confidence in the company's strategic direction.

9 high priority 9 total filings
· daily

S&P 500 Industrials Sector SEC Filings — September 17, 2026

The single filing analyzed for the S&P 500 Industrials stream on September 17, 2026, is a Form 4 from CSX Corp, a major railroad operator. The filing reveals a routine equity award to Director J. Steven Whisler, involving 771 shares valued at approximately $37,500. This transaction is neutral in sentiment and low in materiality, reflecting standard director compensation rather than a signal of management conviction or strategic shift. No other filings from the 33-company universe were submitted on this date, limiting the ability to derive portfolio-level trends or sector-wide patterns. The digest therefore focuses on the implications of this isolated insider activity for CSX, while noting the absence of broader sector movements. Investors should monitor for upcoming earnings calls or capital allocation updates from CSX to assess the company's operational trajectory.

1 high priority 1 total filings
· daily

US Material Events SEC 8-K Filings — September 17, 2026

The September 17, 2026, filing batch reveals a market dominated by significant capital markets activity, with over $8.5 billion in new debt and securitization issuances from companies like Analog Devices, PepsiCo's VW Trust, Hyundai, and Verizon, signaling robust credit demand and refinancing trends. Leadership transitions are widespread across sectors, with notable CEO changes at Accendra Health, Franklin BSP Realty Trust, and Ocean Power Technologies, while several companies like Rexford Industrial and Bank7 Corp are executing strategic portfolio realignments and M&A. A key theme is the divergence between growth-oriented capital raises (e.g., Cenntro's $57M PIPE, Expand Energy's $500M notes) and defensive refinancings to lock in rates or reduce costs (e.g., GMR Solutions' TLB repricing, BRT Apartments' credit facility amendment). However, significant risks emerge from companies like Janus Living, which swung from a $65M profit to a $185M loss, and Healthy Choice Wellness Corp, which faces a going-concern warning despite a $1.25B lease. Insider activity is limited, but the mixed sentiment around Tempest Therapeutics' option deal and the high materiality of the Bank7 acquisition suggest selective opportunities in healthcare and regional banking.

50 high priority 50 total filings
· daily

Insider Trading Pulse — September 17, 2026

This digest covers 50 insider trading filings from September 17, 2026, revealing a clear divergence in management conviction. A massive $1.86B block sale by Diamondback Energy's 10% owner and a $6.2M insider sale at Phillips 66 signal significant bearish sentiment in the energy sector. Conversely, a coordinated insider buying spree at Betterware de Mexico, with executives and directors collectively purchasing ~$2.2M in stock, suggests strong confidence in the company's turnaround. The technology and healthcare sectors show mixed signals, with notable 10b5-1 plan sales at Guardant Health and Halozyme Therapeutics, while Skillsoft Corp. saw insider buying at depressed levels. A major theme is the prevalence of tax-related and 10b5-1 plan sales, which are less directional but still warrant monitoring. The data points to potential value opportunities in consumer goods (Betterware) and small-cap tech (Skillsoft), while raising red flags in energy and specific growth stocks.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — September 17, 2026

This digest covers 16 filings from Dow 30 constituents, dominated by routine equity award disclosures (Microsoft, Cisco, Nike, Procter & Gamble) and a single 8-K from Salesforce. The overwhelming theme is insider compensation via stock and option grants, signaling continued alignment of management with shareholder interests but offering limited trading signals. The most actionable intelligence comes from Salesforce's Investor Day presentation, which contains forward-looking guidance on revenue growth, margin expansion, and cash flow generation, setting a positive tone for the enterprise software sector. No period-over-period comparisons or negative insider activity were present in the filings, making the digest heavily weighted toward neutral, low-materiality events. The key takeaway is a lack of distress signals across these blue-chip names, with capital allocation focused on retaining and incentivizing leadership. Investors should monitor Salesforce's guidance trajectory and watch for any secondary insider sales following the large option grants at Procter & Gamble.

9 high priority 7 medium 16 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 17, 2026

The three filings today paint a stark picture of corporate distress across the US equity markets, with all three companies facing existential threats to their Nasdaq listings. Stardust Power Inc. and Hub Group, Inc. are both at immediate risk of delisting due to non-compliance with listing standards, while CO2 Energy Transition Corp. has been forced to down-list to the Nasdaq Capital Market after its business combination deal fell through. The common thread is a failure to meet basic financial and regulatory requirements, with Hub Group's situation being particularly severe due to its failure to file required periodic reports even after a 180-day extension. The absence of any positive period-over-period trends, insider buying, or capital allocation actions across these filings underscores the depth of their distress. The most critical development is Hub Group's delisting determination, which could trigger a cascade of negative consequences including debt covenant violations and loss of institutional investors. The market implications are clear: investors should avoid these names until concrete turnaround plans are executed, and the broader theme of Nasdaq compliance failures is a red flag for small-cap and micro-cap exposure.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — September 17, 2026

This digest covers 50 filings from September 17, 2026, dominated by M&A, delisting risks, and insolvency proceedings. A major theme is the aggressive acquisition activity in the industrial and energy sectors, with Copart's $9B+ bid for ACV Auctions and Rexford Industrial's $1.2B portfolio sale highlighting significant capital rotation. Delisting and going-concern risks are elevated, with five companies (Hub Group, Stardust Power, Healthy Choice Wellness, Astron Paper, Metal Sky Star) facing existential threats. The tender offer landscape is active, with Beretta Holding's strategic bid for Sturm Ruger and Medtronic's spin-off of MiniMed creating arbitrage opportunities. Insider activity is sparse but notable in the ACV Auctions deal, where major holders have locked in support. Forward-looking data points to a busy Q4 2026 for business combination completions and regulatory decisions. Overall, the digest signals a market in transition, with capital flowing from distressed assets to high-growth infrastructure and healthcare plays, while regulatory and financial distress creates both risks and opportunities.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — September 17, 2026

Today's filings reveal a market bifurcated between aggressive capital deployment in high-growth tech (autonomous vehicles, nuclear energy) and acute distress in micro-cap and pre-revenue companies facing going-concern risks. The most significant development is the convergence of three filings around the May Mobility/ACP Holdings de-SPAC, which targets a $1.4B enterprise value and positions to be the first U.S. public pure-play autonomous ride-hail company, backed by a $120M PIPE. In parallel, NewHold Investment Corp. III shareholders overwhelmingly approved a business combination with newcleo plc (94% support), signaling strong investor appetite for nuclear energy SPACs. On the negative side, Nano-X Imaging and Healthy Choice Wellness Corp. both disclosed substantial doubt about their ability to continue as going concerns, with Nano-X adjourning its AGM due to lack of quorum. Insider activity was mixed but notable: Betterware de Mexico executives collectively bought $2.3M in stock at ~$16.40, while Trevi Therapeutics and American Battery Technology directors sold significant positions. Revenue trends were weak where available, with Innovation Beverage Group reporting a 5.1% YoY decline and a 11.9% two-year drop. Capital allocation patterns show a shift toward debt management, with GMR Solutions repricing $2.9B in debt to save $28M annually and ERP Operating expanding its commercial paper program by $1B.

39 high priority 11 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — September 17, 2026

The 13 enriched filings for the S&P 500 Consumer Discretionary stream are dominated by routine insider equity transactions, primarily tax-withholding exercises by eBay executives and a significant conversion/disposal by Ford's Executive Chair, alongside routine governance updates at TJX, Ross Stores, and Nike. No forward-looking guidance, period-over-period financial comparisons, or capital allocation changes were present in the enriched data, limiting the ability to assess fundamental trends. The most material signal is the large insider activity at Ford, which warrants monitoring for potential overhang, while the eBay insider activity is largely neutral as it reflects standard equity compensation management. The sector theme is one of management teams managing equity compensation and refreshing boards, with no immediate bullish or bearish catalysts identified from the provided data.

12 high priority 1 medium 13 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — September 17, 2026

All five enriched filings originate from Medtronic plc, all related to the ongoing separation of its MiniMed Group via an exchange offer. The filings are predominantly administrative, correcting a typographical error in the guaranteed delivery deadline (from 12:00 midnight to 5:00 p.m. ET) in the offer prospectus, with no change to the financial terms or scope of the transaction. The exchange offer, which commenced September 14, 2026, seeks to swap up to 225.4 million newly issued MiniMed shares (~80.1% of MiniMed) for Medtronic ordinary shares, including an oversubscription option for up to an additional 27.5 million shares. The only insider activity is a small sale by EVP & President Cardiovascular, Harry Skip Kiil, of 1,483 shares (~$139K), which is immaterial relative to holdings. The core investment thesis is the value-unlocking potential of the MiniMed spin-off, which could enhance Medtronic's valuation multiple and sharpen its focus on its core cardiovascular and medtech franchises. The corrected deadline is a time-sensitive operational detail for shareholders, but the primary market catalyst remains the successful completion of the exchange offer and the subsequent listing of MiniMed.

4 high priority 1 medium 5 total filings
· daily

US Earnings Financial Results SEC Filings — September 17, 2026

The 8 filings in this digest, spanning the period from September 17, 2026, to September 17, 2026, reveal a market bifurcated between a few high-growth, high-risk digital asset plays and a cluster of micro-cap companies in severe financial distress. The most material development is UPEXI's 58% YoY revenue surge to $25.0M, driven by a 17.7x explosion in digital asset revenue, yet this is overshadowed by a $246.1M net loss and a $195.1M unrealized loss on digital assets, pushing stockholders' equity to a negative $53.8M. Conversely, 5E Advanced Materials and Paramount Gold Nevada, both in the materials sector, show widening losses but have secured critical financing, with 5E's cash position soaring to $19.5M from $3.8M and Paramount's to $9.9M from $1.4M, signaling a potential runway extension for project development. The remaining micro-caps (Greenlit, Vogenx, VitaSpring, CTT) are characterized by zero revenue, negative equity, and dwindling cash, with Greenlit reporting zero cash and assets, and CTT's cash down to just $31. The VanEck BNB ETF, a new entrant, posted a -14.36% total return since inception, reflecting immediate crypto market volatility. Key themes include a stark divergence in capital access, with companies able to raise equity (5E, Paramount) showing improved liquidity, while others face a funding crunch. The overarching risk is the high concentration of losses in digital asset-related entities, while the opportunity lies in the potential turnaround of well-funded development-stage companies.

8 high priority 8 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 17, 2026

This digest of five proxy filings reveals a bifurcated landscape in executive compensation and corporate governance. While most filings are routine, two companies present actionable intelligence. Regis Corp shows a tangible turnaround with Adjusted EBITDA up 3.8% YoY and a return to positive same-store sales growth, signaling operational recovery. Conversely, Fox Corp's proxy is dominated by the transformative, high-risk proposed acquisition of Roku, which overshadows standard governance items. Luxfer Holdings is in a definitive M&A process, with its proxy detailing the terms of a Scheme of Arrangement, representing a near-certain event-driven opportunity. The filings for Atlas Money Market Fund and Mercury Systems are largely procedural, offering limited actionable insights for executive compensation analysis. A key portfolio-level observation is the absence of significant insider trading activity or aggressive capital allocation signals across the set, suggesting a period of caution or routine governance for most filers.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 17, 2026

The sole filing in this IPO Pipeline digest is GeoVax Labs, Inc.'s S-1 registration statement, which reveals a company in severe financial distress rather than a traditional growth-oriented IPO. The filing is a desperate capital raise attempt amid a Nasdaq delisting threat, with a hearing scheduled for October 13, 2026. Period-over-period data shows a deteriorating equity position, and the company's prior reverse stock split (1-for-25) has eliminated its standard cure period. The negative sentiment and 10/10 materiality score underscore an existential risk for existing shareholders. No bullish signals or growth catalysts are present, making this a high-risk, speculative filing with no clear path to a successful public offering or continued listing.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — September 17, 2026

This digest covers 30 SEC filings from September 17, 2026, focused on executive and director changes. Key themes include a wave of CEO/CFO successions, a notable shift toward independent board leadership, and a significant uptick in performance-based equity grants tied to aggressive stock price targets. The most material event is the pending $163M merger between First Reliance and Colony, now awaiting shareholder approval. While most changes are routine, the concentration of insider sales and the lack of transparency in several filings warrant caution. We identify 10 investment signals, 8 risks, and 8 opportunities, highlighting both stability plays and high-growth catalysts.

30 high priority 30 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 17, 2026

The 30 filings reveal a dynamic period of leadership transitions across US public companies, characterized by a mix of routine successions, strategic hires, and a high-profile merger. Key themes include a notable shift towards external and independent directors with deep industry expertise, significant insider buying by a new CEO, and a clear focus on growth-oriented appointments in financial services. While most changes are neutral-to-positive, the departure of a CEO amid an FTC second request for a pending merger and an unexplained officer change present specific risks. The data suggests a market rewarding companies with clear succession plans and experienced leadership, while penalizing uncertainty.

30 high priority 30 total filings
· daily

US Merger & Acquisition SEC Filings — September 17, 2026

The September 17, 2026, M&A filings reveal a market bifurcated between high-conviction, capital-intensive real estate and healthcare transactions and a flurry of SPACs struggling to complete deals or maintain compliance. The most significant capital movement is in industrial real estate, with Rexford Industrial's $1.2B portfolio sale and Surgery Partners' $796.6M hospital divestiture, both reflecting strategic portfolio realignment to optimize balance sheets. The SPAC sector shows clear distress: two SPACs (Bayview, Ribbon) made routine extension payments to buy time, Fifth Era Acquisition received a Nasdaq deficiency notice for low holder count, and Metal Sky Star fired its auditor amid going-concern warnings. The most transformative deal is Lisata Therapeutics' acquisition of Marea, which will effectively reverse-merge into a cardioendocrine pipeline, diluting legacy shareholders by over 97%. Healthy Choice Wellness Corp. is executing a high-risk reverse merger into a data center project with no revenue and a $27.5M working capital deficit, while Predictive Oncology sold its legacy diagnostics business to complete its pivot to GPU-as-a-Service. Period-over-period data is limited in these 8-K filings, but the forward-looking guidance and capital allocation patterns are rich: Rexford is aggressively buying back stock ($505M YTD), while Lisata's $225M PIPE signals strong institutional appetite for the combined entity's pipeline catalysts in Q4 2027.

10 high priority 10 total filings
· daily

Biotech Small-Cap Approvals — September 16, 2026

Over September 11-14, 2026, the FDA approved 4 products, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 4 'Other' approvals. The period delivered two high-conviction bullish signals—APITEGROMAB-MSTN (ISEMBYLD) from SCHOLAR ROCK INC, an NME with Priority Review and Orphan designations, and FLORETYROSINE F 18 (PIXCLARA) from TELIX PHARMACEUTICALS US INC, also an NME with Priority Review and Orphan status. Two neutral signals came from generic/biosimilar approvals of EPINEPHRINE by ZYDUS PHARMS and DASATINIB by MSN. The dominant theme is a lack of pure oncology NME clustering; however, both approved NMEs leverage Orphan exclusivity, signaling continued FDA appetite for rare disease therapies. Key risk: no peak sales or pricing data is disclosed for any approval, impairing near-term commercial valuation estimates.

4 total filings